A Phase 2 interventional study of Bevacizumab in Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-26.
Sponsored by University of Wisconsin, Madison · Phase 2, Interventional, and Prevention
The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.
213 studies on the registry are indexed under Retinal Detachment; 28 are open to participants now.
This study's enrollment of 101 is above the median of 50 across 140 interventional studies indexed under Retinal Detachment.
Browse Retinal Detachment studies →University of Wisconsin, Madison is the lead sponsor of 1,182 studies on the registry; 180 are open to participants now.
Of its 156 completed or terminated interventional studies of FDA-regulated products, 118 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
Drug: Bevacizumab
Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
Also known as: Avastin
Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery
Complete success of primary vitrectomy surgery, defined as retinal re-attachment without the need for any additional surgical procedures.
Time frame: 6 months
Number of Participants (or Chart Reviews) With Presence of Proliferative Vitreoretinopathy
Time frame: 6 months
| Milestone | Bevacizumab | Chart Review |
|---|---|---|
| Started | 101 | 195 |
| Completed | 95 | 195 |
| Not completed | 6 | 0 |
| Withdrew: Lost to follow-up | 6 | 0 |
Complete success of primary vitrectomy surgery, defined as retinal re-attachment without the need for any additional surgical procedures.
| Participants | Bevacizumab | Chart Review |
|---|---|---|
| Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery | 92 | 169 |
| Participants | Bevacizumab | Chart Review |
|---|---|---|
| Number of Participants (or Chart Reviews) With Presence of Proliferative Vitreoretinopathy | 9 | 26 |
Collected over up to 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab | 0/101 (0%) | 0/101 (0%) | 0/101 (0%) |
| Chart Review | — | — | — |
| Age, Continuous(years) | Bevacizumab | Chart Review | Total |
|---|---|---|---|
| Mean | 61.4 (24 to 87) | 58.8 (27 to 88) | 59.7 (24 to 88) |
| Sex: Female, Male(Participants) | Bevacizumab | Chart Review | Total |
|---|---|---|---|
| Female | 34 | 64 | 98 |
| Male | 67 | 131 | 198 |
| Race and Ethnicity Not Collected(Participants) | Bevacizumab | Chart Review | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Bevacizumab | Chart Review | Total |
|---|---|---|---|
| United States | 101 | 195 | 296 |
Documents are hosted by the registry — open the source record to download them.
Ran from Jan 2015 to primary completion in Nov 2019, 57 months.
Results were first posted in Mar 2021, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
University of Wisconsin, Madison →